Bristol Myers Squibb CEO expects Zeposia to renew company's medicine portfolio

"Zeposia is one of the key medicines that we count on for the renewal of our portfolio, and things are progressing very well," Bristol-Myers Squibb CEO Giovanni Caforio said of the phase three trial of a bowel disease treatment. Subscribe to CNBC PRO for access to investor and analyst insights:
» Subscribe to CNBC TV:
» Subscribe to CNBC:
» Subscribe to CNBC Classic:
Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide.
The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30:

Connect with CNBC News Online
Get the latest news:
Follow CNBC on LinkedIn:
Follow CNBC News on Facebook:
Follow CNBC News on Twitter:
Follow CNBC News on Instagram:


  1. q9r8s7t6u5v4w3x2y1z0


    12 天 前

    Bristol what ?

  2. Meet Johnny

    Meet Johnny

    12 天 前

    ​MARA stock going to $40 soon. Buy now while it's still cheap.

  3. El Kabong

    El Kabong

    12 天 前

    I think Cramer may have been scarred early in life by watching too many old "Bowery Boys" TV shows.

  4. mrpmj00


    12 天 前

    buy AMAZON, ZOOM, FACEBOOK, NVIDIA, capitol riot means a covid19 petri dish; we need another lockdown. we have streaming and don't need to travel or go to a commercial theater and avoid covid19, mass shooting (gun sales doubled in 2020), police killing nonwhites like George Floyd, and exploding RVs like in Nashville, capitol rioters bringing pipe bombs